Neurotech

INVESTOR PRESENTATION

November 2020

BRIDGING TO A BETTER LIFE

Neurotech International Limited (ASX: NTI)

Disclaimer

IMPORTANT INFORMATION

Purpose of presentation: This presentation (including this document, any related video or oral presentation, any question and answer session and any written or oral material discussed or distributed in relation to this presentation) has been prepared by Neurotech International Limited (ACN 610 205 402) (**Neurotech** or **Company**). It has been prepared for the sole purpose of providing general information on Neurotech and its business.

Not an offer or solicitation: This presentation is not investment advice nor an offer to subscribe for securities or otherwise invest in Neurotech, and it should not be relied upon to make any investment decision. Further, it does not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of securities pursuant to this presentation in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful under applicable law, including the Securities Act of 1933 (USA), as amended (**US Securities Act**). Securities have not been registered under the US Securities Act or any US state securities laws and may not be offered or sold in the United States absent registration or an applicable exemption from registration under the US Securities Act and applicable state securities laws.

Not a prospectus: This presentation is not a prospectus, product disclosure statement or other investment disclosure document, and the level of disclosure in this presentation is less than such disclosure documents. It has not been lodged with any regulatory or supervisory body. This presentation does not purport to contain all of the information that a prospective investor may require to make an evaluation of Neurotech or its business activities and nothing in this presentation is, or is intended to be, a recommendation to invest in Neurotech. Neurotech does not purport to give financial or investment advice. Account has not been taken of the objectives, financial situation or needs of any recipient of this presentation.

Forward-looking statements: This presentation contains forward-looking statements which may be predictive in nature and incorporate an element of uncertainty or risk, such as 'intends', 'may', 'could', 'believes', 'estimates', 'targets' or 'expects'. These statements are based on an evaluation of current economic and operating conditions, as well as assumptions regarding future events.

These events are, as at the date of this presentation, expected to take place, but there cannot be any guarantee that such will occur as anticipated, or at all, given that many of the events are outside Neurotech's control. The stated events may differ materially from results ultimately achieved. Accordingly, neither Neurotech nor any of its directors, employees, contractors or advisors make any warranty or assurance that the results, performance or achievements expressed or implied by the forward-looking statements contained in this presentation will actually occur. Further, other than as required by law, Neurotech may not update or revise any forward-looking statement if events subsequently occur or information subsequently becomes available that affects the original forward-looking statement.

Disclaimer: Neither Neurotech nor its officers, employees, contractors or advisers make any warranty (express or implied) as to the accuracy, reliability, relevance or completeness of the material contained in this presentation. Nothing contained in this presentation is, or may be relied upon as a promise, representation or warranty, whether as to the past or the future. Neurotech excludes all warranties that can be excluded by law. Except for statutory liability which cannot be excluded, Neurotech, its officers, employees, contractors and advisers expressly disclaim any responsibility for the accuracy or completeness of the material contained in this presentation and exclude all liability whatsoever (including in negligence) for any loss or damage which may be suffered by any person as a consequence of any information in this presentation or any error or omission therefrom.

Professional advice: Recipients of this presentation should consider seeking appropriate professional financial, taxation and legal advice in reviewing the presentation and all other information with respect to Neurotech and evaluating its business, financial performance and operations.

Proprietary information and copyright: This presentation and the information it contains is proprietary to Neurotech. Neurotech holds the copyright in this presentation. Except as permitted under the Copyright Act 1968 (Australia), this paper or any part thereof may not be reproduced without its written permission.

Overview

Neurotech is focussed on the development & commercialisation of neurological solutions that improve quality of life

Neurotech's Mente device & therapy is clinically proven to increase engagement & improve relaxation in autistic children with elevated delta band brain activity

Mente continues to gain recognition as a therapeutic tool with parents and carers of those with autism spectrum disorder

Neurotech has acquired an exclusive worldwide licence to utilise proprietary cannabis strains from Dolce Cann Global Pty Ltd ('Dolce')

Potential for the Dolce cannabis strains to treat neurological disorders including autism, epilepsy & ADHD

Significant research & clinical studies have highlighted the potential benefit of medicinal cannabis in neurological conditions such as autism

Promising results received from the analysis of 80 cannabis samples as part of genetic profiling & analysis being conducted for Neurotech

Neurotech has commenced human tissue sample trials prior to the commencement of human clinical trials starting in early 2021

The mente device

01

Proven Technology

Mente is world's first home-based brain training therapy that is clinically proven to increase engagement & improve relaxation in autistic children with elevated delta band brain activity

02

Complementary & Versatile

Enables clinics, doctors & therapists to expand their practice into the home with a unique therapy

03

Personalised Therapy

Each Mente device analyses the individual's EEG & delivers personalised brain training in an audio therapy session where the child can continue with their typical morning routine

04

Minimal Disruption

The child continues with their typical routine, supporting them in regular school learning & social activities

Increased recognition of mente globally

relax
engage
focus

CE Marking for the Mente device recently renewed, enabling continued marketing & sales of the device in Europe

Secured Brain Therapeutics as **Mente distributor in Greece**

Added to **UK's National Autism Services Directory**



Mente therapy referral program adopted by Norcal Brain Center (USA) and Australasian Neurofeedback Institute (ANFI)

Featured in **Autism Parenting Magazine** in USA

Neurotech licences cannabis strains targeting autism

- Neurotech has acquired an exclusive worldwide license to utilise proprietary cannabis strains from Dolce Cann Global
- Potential for these strains in medicinal use to treat neurological disorders including autism, epilepsy & ADHD
- Dolce's proprietary genetics are sourced from 13 rare landrace chemovars developed over 20 years using selective targeted breeding techniques
- Genetic profiling of approximately 650 leaf cuttings from Dolce seedlings evidenced high levels of specific cannabinoids including CBG, CBC, CBN & CBDV – each of which have shown potential in neurological disorders
- Complements Neurotech's existing Mente technology

Significant potential for cannabis in neurological disorders

Phytocannabinoids are being analysed in studies around the world to determine their influence over the brain's CB1 and CB2 receptors

The expectation is that phytocannabinoids can stimulate the endocannabinoid system in the body, sending targeted signals to address health conditions

The momentum in this research area has seen symposiums & conferences dedicated to the potential benefits of medicinal cannabis in autism

120+ phytochemicals in cannabis plant – studies indicate certain strains may provide relief from neurological disorders including autism:

- Israel's Ben Gurion University of the Negev released findings of a study in 188 children with autism who used cannabis oil for six months, with more than 80% showing 'significant or moderate improvement' as well as positive impacts on quality of life, mood and sleep/concentration[1]
- Murdoch Children's Research Institute found cannabidiol may reduce severe behavioural problems in intellectually impaired children & adolescents[2]. Clinical studies are furthering this investigation including a Phase 2 study by NYU Langone Health[3].



Neurotech

[1] https://www.healtheuropa.eu/cannabis-and-autism-children/93274/
[2] https://www.sciencedaily.com/releases/2020/06/200624100039.htm
[3] https://clinicaltrials.gov/ct2/show/NCT03900923?term=cbd&cond=Autism&draw=2

Results from Neurotech's cannabinoid analysis

- Final results from Neurotech's analysis of 80 cannabis samples from the Dolce Cann Global genetic portfolio return a variety of cannabinoids, including newly discovered phytocannabinoids CBDP and CBDB
- All 80 samples contained varying amounts of all major cannabinoids – CBDV, CBDA, CBGA, CBG, CBD, THCV, CBN, THC, d8-THC, CBC and THCA
- Neurotech's samples contained CBDA levels up to approx. 12% — CBDA can act as a regulator in neuro-modulation, with powerful anti-anxiety and anti-inflammatory properties
- Samples were analysed using well-established and published High Performance Liquid Chromatography Ultraviolet (HPLC/UV) and Mass Spectrometry (MS) methods
- NTI has commenced in-vitro testing (using human derived cell lines) on key priority strains
- If in-vitro testing is successful, Neurotech will commence clinical trials with an Australian university, utilising Dolce cannabis strains and its own proprietary Mente neurofeedback device which analyses brain wave activity

Expected pathway of cannabis project

1. In vitro assay assessments

Neuronal or muscle cell line assessments

Analytical assessments & validation program to be completed in collaboration with Monash University, RMIT University and University of Wollongong. These studies are to assess:

- Dose response studies
- Upper level of toxicity assessments
- Mechanism of action profiling
- Selection of top candidates

2. Product formulation and final dose profiling

To be conducted in collaboration with Cannabis Formulation Experts and ACS Laboratories

Final product application: i.e. Spray, tincture, oil

Final specification sign off

3. Small scale human (efficacy) clinical trials

Commencing in early 2021 - to be conducted in conjunction with a leading Australian University and clinician on the following basis:

- Open label – single group
- Compassionate use scheme to receive entry into clinic via accelerated pathway (SAS Cat B)
- Collaboration with senior clinical advisors
- Submission to the TGA and relevant regulatory bodies

Preliminary Results from In vitro Studies

Studies were designed to assess the **neuroprotective** and **neuro-modulatory** activities of the top DOLCE/NTI cannabis strains.

Studies were conducted in human derived brain and muscle cells – these models are internationally accepted and used to assess the efficacy and mechanism of neurological actives.

Key Findings

In all studies the top DOLCE/NTI strains demonstrated superiority when compared to CBD alone.

- DOLCE/NTI strains demonstrated reduction in brain cell inflammation (up to 60%)
- DOLCE/NTI strains demonstrated an increase in overall brain cell health and viability (in the absence of toxic insult up to 80%)
- DOLCE/NTI strains demonstrated an increase in mitochondrial viability and output (in the presence of toxic insult up to 60%)

Inflammation, cell and mitochondrial viability are all very important processes and outcomes in understanding, maintaining brain function and cognitive health.

Results clearly demonstrate the powerful neuroprotective and neuro-modulatory properties of the DOLCE/NTI strains and superiority when compared to current market standard: **CBD isolate**

Studies pave the way forward in designing the optimum clinical design program and clinical indication/s.

Neurological Disorders Market Opportunity

Global market for neurological disorder treatment is estimated to be US$112b per year by 2027 growing at 5% p.a.

The global medical marijuana market was valued at *US$11.4bn in 2015 and is expected to continue to grow at exponential rates as adoption increases and treatment development advances

The World Health Organization estimated that in 2006, as many as [1]one billion people worldwide suffered from a neurological disorder[1]. The number of those affected by neurological disorders will continue to increase as the world's population grows.

Over 4 million registered medicinal cannabis patients in the US alone[2], other countries are following the US's adoption of cannabinoid-based treatments

Neurotech's unique cannabis strains have the potential to be used for medicinal use in treating neurological disorders including autism, epilepsy and ADHD.

*WHO Neurological Disorders: Public Health Challenges

[1]Prohibition Partners: North American Report 2019

[2]Grandview Research. Medical Marijuana Market Analysis By Application, By Country, And Segment Forecasts, 2018 - 2025

Industry Peer Overview

Company	Neurotech International	Zelira Therapeutics	Cann Global	India Globalisation Capital	Botanix Pharmaceuticals
Ticker	ASX: NTI	ASX: ZLD	ASX: CGB	NYSE: IGC	ASX: BOT
Market Capitalisation	~$15m	~$86m	~$26m	~US$53m	~$102m
Description	Development of neurological solutions that improve quality of life	Therapeutic medicinal cannabis for the treatment of a variety of medical conditions	Hemp and medicinal cannabis product developer	Treatment of life-threatening conditions with phytocannabinoid-based therapies	Pharmaceutical company leveraging the unique properties of synthetic cannabinoids
Product Stage	In-vitro trials	Clinical Stage	Commercial Sales	Commercial Sales	Clinical Stage

Highly Experienced Board

Brian Leedman
Chairman
(Non-Exec)

- More than 15 years' experience in the biotechnology sector
- Founder or co-founder of five ASX listed healthcare/ biotechnology companies including: RAP, NGS, NSB, OSL, IMU
- Former Chairman of Ausbiotech (WA)
- BEc, MBA (UWA), AICD

Mark Davies
Non-Exec
Director

- More than 20 years' experience in trading, investment banking & providing corporate advice
- Specialises in providing corporate advice & capital raising services to emerging companies seeking business development opportunities and funding from the Australian market
- Managing Director of 1861 Capital, also worked at Montagu Stockbrokers before co-founding investment banking firm Cygnet Capital
- BCom

Winton Willesee
Non-Exec
Director

- Experienced company director with over 20 years experience in various roles within the Australian capital markets
- Core expertise in strategy, company development, corporate governance, company public listings, merger and acquisition transactions and corporate finance
- MCom, FFin, CPA, GAICD, FGIA/FCG

Corporate Overview

CAPITAL STRUCTURE	
Share price (as at 13 Nov 2020)	$0.03
Shares on issue	500.6m
Options	161.32m^
Cash at bank	~$2,000,000
Market capitalisation	$15m

^Options have various strike prices between $0.005 to $0.20



CONTACT DETAILS

Brian Leedman
Chairman
b.leedman@neurotechinternational.com
+61 412 281 780

Winton Willesee
Non-Executive Director
winton@azc.com.au
+61 410 667 844

This presentation has been authorised for release by the Board of Neurotech International Limited.

www.neurotechinternational.com
www.mentetech.com

Neurotech

Neurotech International Limited (ASX: NTI)